Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis

Jie-Hui Zhong _, Dan-Hui Huang and Zi-Yu Chen

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:75381-75388. https://doi.org/10.18632/oncotarget.18856

Metrics: PDF 2140 views  |   HTML 3784 views  |   ?  


Jie-Hui Zhong1, Dan-Hui Huang1 and Zi-Yu Chen1

1Department of Clinical Medicine, The First Clinical Medical College, Southern Medical University, Guangzhou, 510515, China

Correspondence to:

Jie-Hui Zhong, email: [email protected]

Keywords: systemic immune-inflammation index, solid tumors, meta-analysis

Received: April 05, 2017     Accepted: June 10, 2017     Published: June 29, 2017


Background: Inflammation may play an important role in cancer progression, and a higher systemic immune-inflammation index (SII) has been reported to be a poor prognostic marker in several malignancies. However, the results of published studies are inconsistent.

Materials and Methods: A systematic review of databases was conducted to search for publications regarding the association between blood SII and clinical outcome in solid tumors with a date up to February 12, 2017. The primary outcome was overall survival (OS) and the secondary outcomes were progression-free survival (PFS) and cancer-specific survival (CSS). Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were used to assess the strength of the association between blood SII and clinical outcome in solid tumors.

Results: A total of 15 articles were included in the analysis. Overall, systemic immune-inflammation index greater than the cutoff predicted poor overall survival (HR = 1.55, 95% CI = 1.27–1.88; P < 0.001). Subgroup analyses revealed that high systemic immune-inflammation index indicated a worse overall survival in hepatocellular carcinoma (P < 0.001), urinary cancers (P < 0.001), gastrointestinal tract cancers (P = 0.02), small cell lung cancer (P < 0.05) and acral melanoma (P < 0.001). Hazard ratio for systemic immune-inflammation index greater than the cutoff for cancer-specific survival was 1.44 (P < 0.05).

Conclusions: Elevated systemic immune-inflammation index is associated with a worse overall survival in many solid tumors. The systemic-inflammation index can act as a powerful prognostic indicator of poor outcome in patients with solid tumors.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18856